ICER first assessed the cost-effectiveness of alirocumab and evolocumab (Repatha®, Amgen) shortly after these drugs were first granted regulatory approval in the US in 2015, and performed a New Evidence Update for evolocumab in September 2017, following the release of outcomes data from the FOURIER trial. This Final New Evidence Update is the revised version of ICER's preliminary analysis of the ODYSSEY Outcomes data initially presented at the American College of Cardiology's 2018 Scientific Session. Today's announcement does not alter ICER's analysis of the FOURIER trial, which concluded that a value-based price benchmark for a year's treatment with evolocumab would be between $1,700 and $2,200.